Cvrx, Inc. (CVRX) Stock Price & Analysis

Cvrx, Inc. (CVRX) fell 3.07% to USD 4.74 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.

CVRX last closed at USD 4.89; the session ranged USD 4.7–4.99 on volume of 196,046 shares. Market capitalization is $125.78M, with a 52-week range of USD 4.37–11.3 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.

Key Statistics (as of July 25, 2026 at 03:04 UTC)

Technical Analysis (CVRX)

Nexqual's technical model rates CVRX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.

Analyst Ratings (CVRX)

Wall Street analysts rate CVRX "Buy" based on 6 analysts, with a mean price target of USD 11.17 (range USD 6–14), per Nexqual as of July 25, 2026 at 03:04 UTC.

Earnings (CVRX)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Financials & Fundamentals (CVRX)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Financial Health Score (CVRX)

Nexqual rates Cvrx, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:04 UTC.

Ownership (CVRX)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

Leadership (CVRX)

Cvrx, Inc. is led by Kevin Hykes (age 59), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:04 UTC.

Major Backers & Investors (CVRX)

Notable institutional backers of Cvrx, Inc. include Johnson & Johnson, NEA Management Company, LLC, GSK plc, according to Nexqual as of July 25, 2026 at 03:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:04 UTC.

From Cvrx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe Barostim offers meaningful benefits for patients, physicians and payers that will continue to drive adoption of our therapy.   Overview of Barostim Therapy Our integrated platform technology, Barostim, leverages the power of the brain and its ANS to address the primary cause of HFrEF and other cardiovascular diseases.
• In December 2014, after a favorable review of the long-term clinical data from the Rheos pivotal hypertension trial, the FDA granted the HDE to Barostim Legacy. ​ Since 2011, we have completed one clinical trial in Europe and North America for the treatment of drug-resistant hypertension using Barostim (" Minimally Invasive System for Baroreflex Activation Therapy Chronically Lowers Blood Pressure with Pacemaker-like Safety Profile: Results from the Barostim Neo Trial ," by Uta C.
• Our patents cover aspects of our integrated platform technology, Barostim, including baroreflex methods, stimulus regimes, mapping methods, electrode designs, disease treatments, closed loop control, burst intervals, connection structures and baroreceptor locations, as well as future product concepts.
• We protect our proprietary rights through a variety of methods, including confidentiality and assignment agreements with suppliers, employees, consultants, and others who may have access to our proprietary information. ​ Pending patent applications may not result in issued patents, and we cannot guarantee that any current or subsequently issued patents will protect our intellectual property rights or provide us with any competitive advantage.

Partnerships

• We designed our BeAT-HF (Phase III) pivotal trial in collaboration with the FDA under the Breakthrough Devices Program, which was implemented to accelerate the approval of novel therapies targeting unmet needs for debilitating or life-threatening conditions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.